About Protalix BioTherapeutics
Protalix BioTherapeutics is a company based in Karmiel (Israel) founded in 1993. The company has 213 employees. Protalix BioTherapeutics offers products and services including Elfabrio®, Elelyso®, and ProCellEx®. Protalix BioTherapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Karmiel, Israel
- Employees 213
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website protalix.com
- Social LinkedIn
- Legal Name Protalix Biotherapeutics, Inc. (De)
- Annual Revenue$52.74 M (USD)-1.23as on Dec 31, 2025
- Net Profit-$6.6 M (USD)-325.24as on Dec 31, 2025
- EBITDA-$4.04 M (USD)-177.28as on Dec 31, 2025
- Latest Funding Round$43.7M (USD), Post-IPO
Mar 2020
- InvestorsUBS
& 11 more
- Employee Count213
Products & Services of Protalix BioTherapeutics
Protalix BioTherapeutics offers a comprehensive portfolio of products and services, including Elfabrio®, Elelyso®, and ProCellEx®.
Treats Fabry disease through recombinant protein administration.
Addresses Gaucher disease with therapeutic protein solutions.
Enables plant-based production of recombinant therapeutic proteins.
Funding Insights of Protalix BioTherapeutics
- Total Rounds 9
- Last Round Post-IPO — $43.7M
- First Round $3.5M
(Oct 2004)
- Investors Count 12
All 9 funding rounds of Protalix BioTherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $43.7M | Post-IPO | – | – | |
| Jan 2017 | $986,803 | Grant | – | – | |
| Oct 2015 | $10M | Post-IPO | – | – | |
| Sep 2013 | $69M | Post-IPO | – | – | – |
| Mar 2011 | $22M | Post-IPO | – | – | – |
| May 2010 | $4.1M | Grant | – | – | – |
| Jan 2009 | $499,825 | Grant | – | – | |
| Dec 2005 | $7.6M | Post-IPO | – | – | |
| Oct 2004 | $3.5M | Post-IPO | – | – | – |
12 investors in total: 12 institutional.
Investors in Protalix BioTherapeutics
Protalix BioTherapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include UBS, Pfizer and Mor Investment House.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-short strategy hedge fund and venture capital firm investing in tech companies | 2006 | moreinvest.co.il | Ramat Gan, Israel | |
- | – | marathon.co.il | - | |
Investments are directed toward Israeli technology startups by Docor. | – | docor.com | Tel Aviv, Israel | |
Diversified investment management services are provided across asset classes. | 1963 | psagot.co.il | Tel Aviv, Israel | |
- | – | highbridge.com | - | |
Financial services are provided globally by UBS for wealth management. | 1862 | ubs.com | Zurich, Switzerland | |
Offers sales and investment in gold, silver, and precious metals products. | 2008 | roslandcapital.com | Los Angeles, United States | |
Real estate brokerage services are provided in Israel. | 1978 | alrov.co.il | Tel Aviv, Israel | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Protalix BioTherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Protalix BioTherapeutics
26 people are tracked at Protalix BioTherapeutics (10 in leadership, 10 in board & advisors, 6 in team); the tracked headcount is 213.
| Name | Role | Group |
|---|---|---|
Gilad Mamlok | Chief Financial Officer | Leadership |
Tanya Gershanik | VP, Quality Affairs | Leadership |
Dror Bashan | President, CEO & Director | Leadership |
Yael Fellous | VP, Human Resources | Leadership |
Dafna Shelly | VP Human Resources | Leadership |
Dr Tanya Gershanik | VP Quality Affairs | Leadership |
Yoram Cohen | Senior Director Supply Chain | Leadership |
Ofir Fogel | Senior Director Of Finance | Leadership |
Shoshi Tessler | VP Clinical Development And Regulatory Affairs | Leadership |
Sheli Levy | Senior Director Information Technology | Leadership |
Aharon Schwartz | Director | Board & advisors |
Pol F. Boudes | Director | Board & advisors |
Amos Bar Shalev | Director | Board & advisors |
Alexander Levitzki | Scientific Advisor | Board & advisors |
Zeev Bronfeld | Chairman | Board & advisors |
Charles J. Arntzen | Scientific Advisor | Board & advisors |
Shmuel Ben Zvi | Director | Board & advisors |
Gwen A. Melincoff | Director | Board & advisors |
Roger D. Kornberg | Scientific Advisor | Board & advisors |
Raul Chertkoff | Senior Advisor | Board & advisors |
6 more people are available in the full profile.
Complete people profiles for Protalix BioTherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Protalix BioTherapeutics
Protalix BioTherapeutics is a publicly listed company on the AMEX with ticker symbol PLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Mar 2007
- Listed onNYSE: PLX
- Listed entityProtalix BioTherapeutics, Inc. (DE)
- Exchange sectorHealth technology
- ISINUS74365A3095
- Share price$2.78 (+2.96% on the day) · 2026-10-09
- Market capitalisation$224.0M
- Price to earnings12.2
- EPS (diluted, trailing year)$0.23
- Volume (last session)1,198,885
Financials of Protalix BioTherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $52.7M | -$6.6M | -$4.0M |
| 2024 | $53.4M | $2.9M | $5.2M |
| 2023 | $65.5M | $8.3M | $11.7M |
| 2022 | $47.6M | -$14.9M | -$11.9M |
| 2021 | $38.4M | -$27.6M | -$19.3M |
Detailed financial statements for Protalix BioTherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Protalix BioTherapeutics
4 dated milestones of Protalix BioTherapeutics across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Protalix BioTherapeutics is founded.
- Funding First funding round of $3.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $43.7M.
Competitors of Protalix BioTherapeutics
Protalix BioTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Protalix BioTherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Protalix BioTherapeutics
The website of Protalix BioTherapeutics (protalix.com) receives about 6.5K visits a month and ranks #3,462,636 among all websites worldwide, #4,503 in Biotechnology and Pharmaceuticals.
- Monthly visits6.5K
▲ 17.5% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,462,636
among all websites
- Category rank#4,503
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.7
- Average visit44 sec
- DevicesDesktop 47% · Mobile 53%
Websites whose visitors overlap most with Protalix BioTherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| tepnel.com | 98% | – | – | View details | |
| recombinetics.com | 87% | 2.4K | #8,168,921 | View details |
Latest news on Protalix Biotherapeutics
Complete news archive for Protalix BioTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Protalix BioTherapeutics
10 companies that operate in the same segment as Protalix BioTherapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Protalix BioTherapeutics
Protalix BioTherapeutics was founded in 1993 and raised its 1st funding round 11 years after it was founded.
Protalix BioTherapeutics is headquartered in Karmiel, Israel. It is registered at Karmiel, Northern District, Israel.
Protalix BioTherapeutics has 213 employees.
Annual revenue of Protalix BioTherapeutics is $52.74M as on Dec 31, 2025.
Protalix BioTherapeutics was founded in 1993 in Karmiel, Israel, and operates in the biotechnology sector. Recombinant proteins are developed and commercialized using the ProCellEx plant cell expression system. A pipeline of novel and biosimilar proteins is pursued, with ELELYSO marketed as a glucocerebrosidase enzyme for Type 1 Gaucher disease. Additional recombinant proteins are under development for Fabry disease, immune and inflammatory conditions, and cystic fibrosis.
Protalix BioTherapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Protalix BioTherapeutics offers Elfabrio®, Elelyso®, and ProCellEx®.
Yes, Protalix BioTherapeutics is publicly traded on AMEX under the ticker symbol PLX.
Protalix BioTherapeutics has 12 investors. Key investors include UBS, Pfizer, Mor Investment House, European Union, and Alrov.
Protalix BioTherapeutics operates through Protalix Biotherapeutics, Inc..